Related Experiment Videos

[Association between CYP1A1 gene polymorphism and intrahepatic cholestasis of pregnancy]

Xiaoli Wang1, Li Zhang, Rong-qing Ou

  • 1Department of Obstetrics and Gynecology, the Second People's Hospital of Chengdu, Chengdu, Sichuan, 610017 People's Republic of China.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi = Zhonghua Yixue Yichuanxue Zazhi = Chinese Journal of Medical Genetics
|February 6, 2008
PubMed

Insights

The Ile/Val genetic variation in the CYP1A1 gene is linked to an increased risk of intrahepatic cholestasis of pregnancy (ICP). However, MspI polymorphism in CYP1A1 shows no association with ICP susceptibility.

Area of Science:

  • Genetics
  • Obstetrics
  • Pharmacogenomics

Context:

  • Intrahepatic cholestasis of pregnancy (ICP) is a serious pregnancy complication.
  • Genetic factors are implicated in ICP development, but specific gene associations require further investigation.
  • The cytochrome P450 family 1 member A1 (CYP1A1) gene plays a role in xenobiotic metabolism and has been studied in various diseases.

Purpose:

  • To investigate the association between CYP1A1 genetic polymorphisms (MspI and Ile/Val) and the risk of developing ICP.
  • To determine if specific CYP1A1 genotypes influence ICP susceptibility in a Chinese population.

Summary:

  • A case-control study in Chengdu, China, analyzed 100 ICP cases and 100 controls.
  • CYP1A1 gene polymorphisms were assessed using PCR-RFLP and ASA-PCR methods.
  • Results indicated that Ile/Val+Val/Val genotypes of CYP1A1 significantly increased ICP risk (OR=1.768, P=0.047), while MspI polymorphism showed no significant correlation.

Impact:

  • The Ile/Val polymorphism in CYP1A1 exon 7 may contribute to ICP susceptibility in the studied population.
  • These findings highlight potential genetic markers for ICP risk assessment.
  • Further research can explore the functional mechanisms underlying this association.
Abstract

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...